# Lindy Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lindy-biosciences

- Industry: Biotechnology
- Headquarters: US
- Website: www.lindybio.com
- Total disclosed funding: $1.6M
- Latest round: Series A (Apr 22, 2019)
- Investors on record: 5

## About

Lindy Biosciences is dedicated to advancing biotherapeutics through innovative drug delivery technologies, particularly its proprietary Microglassification™ platform, enhancing patient autonomy and comfort in medication administration.Founded in 2017 and headquartered in the United States, Lindy Biosciences focuses on transforming the administration of biotherapeutics. The company, led by CEO Deborah Bitterfield, has secured a total of USD 1.60 mn across two funding rounds, with the most recent being a Series A funding on April 22, 2019, co-led by Alumshares and Blue Tree Allied Angels, among others.Lindy Biosciences specializes in innovative biotherapeutics drug delivery solutions, with a primary focus on its proprietary Microglassification™ technology. This core product enables the self-administration of medications in home settings, aiming to alleviate the burdens associated with traditional intravenous infusions, which are commonly administered in acute care environments. By transforming the administration of antibody therapeutics, Lindy seeks to enhance patient comfort and autonomy, ultimately improving the quality of life for individuals managing chronic illnesses. The company's offerings cater to a broad range of healthcare providers and patients globally, particularly in markets across North America and Europe, where the demand for accessible and patient-centric treatment solutions is growing.Lindy Biosciences operates within a business model that emphasizes partnerships and collaborations with industry stakeholders involved in biotherapeutic development. The revenue streams are generated through strategic partnerships where clients utilize the Microglassification platform to enhance their own drug delivery products. This collaborative approach includes agreements structured around joint development initiatives, where revenue is accrued based on the successful integration of Lindy’s technology into clients’ offerings. The company’s flagship Microglassification technology serves as a significant focal point for these transactions, as clients seek to leverage its capabilities to improve their therapeutic delivery methods. Specific pricing structures and transaction details are tailored based on the nature of each partnership and the scope of the services provided.Lindy Biosciences plans to leverage its recent Series A funding of USD 1.60 mn, raised in April 2019, to support the development of new products aimed at enhancing its Microglassification technology. Additionally, the company is targeting expansion into key markets across North America and Europe, with an aggressive timeline to establish a broader footprint in these regions by the end of 2023. These initiatives will be crucial in fulfilling the increasing demands for innovative drug delivery solutions in the biotherapeutics sector.

## Funding rounds

- Series A, Apr 22, 2019, $1.6M — Blue Tree Allied Angels, Charleston Angel Partners, Next Act Fund, IAG Capital Partners, Alumshares

## Investors

- Blue Tree Allied Angels — Series A
- Charleston Angel Partners — Series A
- Next Act Fund (https://capitalatlas.ai/funds/next-act-fund) — Series A
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Series A
- Alumshares (https://capitalatlas.ai/funds/alumshares) — Series A